New protease inhibitors and non-nucleoside reverse transcriptase inhibitors

Journal of HIV Therapy

Volumn 13, Issue 2, 2008, Pages 40-44

  Lascar, R Monica ^a   Cartledge, Jonathan D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DRUG METABOLIZING ENZYME; EFAVIRENZ PLUS NEVIRAPINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ERGOT DERIVATIVE; ETRAVIRINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS TIPRINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEDATIVE AGENT; SIMVASTATIN; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MULTIDRUG RESISTANCE; RHABDOMYOLYSIS; SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIDAZINES; PYRIDINES; PYRONES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 52249119386     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Surleraux DL, de Kock HA, Verschueren WG et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med Chem, 2005, 48, 1965-1973.
2. Surleraux DL, Tahri A, Verschueren WG et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem, 2005, 48, 1813-1822.
3. King NM, Prabu-Jeyabalan M, Nalivaika EA et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol, 2004, 78, 12012-12021.
4. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet, 2007, 369, 1169-1178.
5. Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet, 2006, 368, 466-475.
6. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS, 2005, 19, 685-694.
7. Benson CA, Deeks SG, Brun SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis, 2002, 185, 599-607.
8. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2007. Abstract H-718b.
9. Vispo E. Warning on hepatotoxicity of darunavir. AIDS Rev, 2008, 10, 63.
10. de Meyer S, Vangeneugden T, van Baelen BG et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008, 24, 379-388.
11. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med, 2007, 8, 259-264.
12. Boffito M, Maitland D, Pozniak A. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J Clin Pharmacol, 2006, 46, 130-139.
13. Doyon L, Tremblay S, Bourgon L et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res, 2005, 68, 27-35.
14. Naeger LK, Struble KA. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS, 2007, 21, 179-185.
15. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med, 2005, 13, 125-131.
16. Poveda E, de Mendoza C, Parkin N et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS, 2008, 22, 611-616.
17. Pierone G, Jr, Urban T, Martin A et al. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir. HIV Clin Trials, 2008, 9, 140-141.
18. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007, 370, 39-48.
19. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007, 370, 29-38.
20. Haubrich R, Cahn P, Grinsztejn B et al.; on behalf of the DUET-1 study group DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1 infected patients. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 790.
21. Johnson M, Campbell T, Clotet B et al.; on behalf of the DUET-2 study group. DUET-2: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 791.
22. Vingerhoets J, Buelens A, M et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. XVI International HIV Drug Resistance Workshop, Barbados, June 2007. Abstract 32.
23. Picchio G, Vingerhoets J, Staes M et al. Prevalence of TMC125 resistance-associated mutations in a large panel of clinical isolates. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008. Abstract 866.
24. Vingerhoets J, Peeters M, Azijn H et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data. XVIIth International HIV Drug Resistance Workshop, Sitges, June 2008. Abstract 24.
25. Peeters M, Nijs S, Vingerhoets J et al. Determination of phenotypic clinical cut-offs for etravirine: pooled week 24 results of the DUET-1 and DUET-2 trials. XVIIth International HIV Drug Resistance Workshop, Sitges, June 2008. Abstract 121.
26. Coakley E, Chappey C, Benhamida J et al. Biological and clinical cut-off analysis or etravirine in the PhenoSense HIV assay. XVIIth International HIV Drug Resistance Workshop, Sitges, June 2008. Abstract 122.